BNTX vs ROIV
BioNTech SE and Roivant Sciences Ltd., both Healthcare
BioNTech SE is the larger company at $23B against $23B. Over the past year ROIV returned +218% against +1.1% for BNTX. Ryufin's sector-relative Smart Score puts ROIV ahead, 7/10 against 5/10.
| Figure | BNTX | ROIV |
|---|---|---|
| Last close | $113 | $36.77 |
| Market cap | $23B | $23B |
| 1-year return | +1.1% | +218% |
| 5-year return | -66% | +272% |
| Ryufin Smart Scoresector-relative, 1–10 | 5/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BioNTech SE
Roivant Sciences Ltd.
Revenue of $3M in Q4 2025, net income $303M.
Open these two in the interactive comparison to add more names, change the period or read the correlation.